Company Description
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis.
Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial.
Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 176 |
| CEO | Joseph Payne |
Contact Details
Address: 10628 Science Center Drive, Suite 250 San Diego, California 92121 United States | |
| Phone | 858 900 2660 |
| Website | arcturusrx.com |
Stock Details
| Ticker Symbol | ARCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001566049 |
| CUSIP Number | 03969T109 |
| ISIN Number | US03969T1097 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph E. Payne M.Sc. | Founder, President, Chief Executive Officer and Director |
| Dr. Padmanabh Chivukula Ph.D. | Founder, Chief Scientific Officer, Chief Operating Officer and Secretary |
| Andrew H. Sassine MBA | Chief Financial Officer and Director |
| Lance Kurata | Chief Legal Officer |
| Neda Safarzadeh | Vice President and Head of IR/PR and Marketing |
| Natasha O. Bowman | Chief Human Resources Officer |
| Kevin T. Skol | Chief Business Officer |
| Dr. Juergen Froehlich FCPh, M.D., MBA | Chief Medical Officer |
| Dr. Igor Smolenov M.D., Ph.D. | Chief Development Officer |
| Roberta Duncan | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2024 | CT ORDER | Filing |
| Feb 14, 2020 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 1, 2019 | 8-K | Current Report |
| Jun 21, 2019 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 20, 2019 | 8-K | Current Report |
| May 20, 2019 | 8-K | Current Report |
| May 13, 2019 | 8-K | Current Report |
| May 13, 2019 | 10-Q | Quarterly Report |
| Apr 12, 2019 | EFFECT | Notice of Effectiveness |
| Apr 12, 2019 | 424B3 | Prospectus |